Literature DB >> 8768879

Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas.

M Losa1, M Giovanelli, L Persani, P Mortini, G Faglia, P Beck-Peccoz.   

Abstract

The recorded number of patients with central hyperthyroidism due to TSH-secreting pituitary adenoma doubled in the last few years after the introduction of ultrasensitive TSH assays in the assessment of thyroid function; however, information about the results and the criteria for cure after pituitary surgery is scanty. Seventeen patients with a TSH-secreting adenoma, diagnosed on the basis of detectable TSH levels in the face of high free thyroid hormone concentrations and pituitary lesion at neuroimaging, underwent pituitary surgery. Hypersecretion of other pituitary hormones was diagnosed in 5 of 17 patients. Four patients were initially misdiagnosed and treated with thyroid surgery or radioiodine therapy. The majority (86%) of hyperthyroid patients normalized thyroid hormone concentrations and regained euthyroidism, although pituitary imaging, alpha-subunit, and alpha-subunit/TSH molar ratio normalized in only 47%, 54%, and 58% of patients, respectively. Moreover, TSH secretion was normally suppressed by T3 in 40% of the patients. Interestingly, the finding of undetectable TSH levels 7 days after surgery was highly predictive of successful outcome. During long term follow-up, there was one relapse of hyperthyroidism. Early diagnosis of TSH-secreting adenomas permits a high rate of remission of hyperthyroidism after surgery. However, normalization of thyroid function alone does not necessarily reflect complete removal of the tumor, and more comprehensive criteria of cure based on pituitary imaging, hormone measurement, and suppression of TSH during T3 administration should be used. Lastly, all patients need an accurate long term follow-up to monitor the possible recurrence of the adenoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8768879     DOI: 10.1210/jcem.81.8.8768879

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.

Authors:  Cihangir Erem; Arif Hacihasanoglu; Ahmet Sari; Halil Onder Ersöz; Kubilay Ukinç; Sami Fidan
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

Review 2.  A 2019 update on TSH-secreting pituitary adenomas.

Authors:  P Beck-Peccoz; C Giavoli; A Lania
Journal:  J Endocrinol Invest       Date:  2019-06-07       Impact factor: 4.256

3.  Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.

Authors:  M Losa; R L Barzaghi; P Mortini; A Franzin; F Mangili; M R Terreni; M Giovanelli
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 4.  Medical management of thyrotropin-secreting pituitary adenomas.

Authors:  Paolo Beck-Peccoz; Luca Persani
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

5.  Thyrotropin-secreting pituitary adenomas: diagnosis and management of patients from one Chinese center.

Authors:  Weiwei Zhao; Hongying Ye; Yiming Li; Linuo Zhou; Bin Lu; Shuo Zhang; Jie Wen; Shiqi Li; Yehong Yang; Renming Hu
Journal:  Wien Klin Wochenschr       Date:  2012-10-10       Impact factor: 1.704

6.  TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide.

Authors:  M P Fischler; W H Reinhart
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

7.  2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.

Authors:  P Beck-Peccoz; A Lania; A Beckers; K Chatterjee; J-L Wemeau
Journal:  Eur Thyroid J       Date:  2013-05-07

8.  Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.

Authors:  P Iglesias; J J Díez
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

9.  Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience.

Authors:  E Macchia; M Gasperi; M Lombardi; L Morselli; A Pinchera; G Acerbi; G Rossi; E Martino
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

Review 10.  Medical therapy of pituitary adenomas: effects on tumor shrinkage.

Authors:  Annamaria Colao; Rosario Pivonello; Carolina Di Somma; Silvia Savastano; Ludovica F S Grasso; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.